Soluble Ligand of the Immune Checkpoint Receptor (sPD-L1) in Blood Serum of Patients with Renal Cell Carcinoma
暂无分享,去创建一个
A. A. Morozov | E. Gershtein | N. Kushlinskii | M. Filipenko | M. Filipenko | I. Kazantseva | S. Bezhanova | A. Alferov | V. Bazaev | I. O. Goryacheva
[1] A. A. Morozov,et al. Modern approaches to kidney cancer immunotherapy , 2018, Cancer Urology.
[2] Z. Shao,et al. Prognostic Value of Programmed Cell Death 1 Ligand-1 (PD-L1) or PD-1 Expression in Patients with Osteosarcoma: A Meta-Analysis. , 2018, Journal of Cancer.
[3] Juan Wang,et al. High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma , 2018, Translational oncology.
[4] A. Osunkoya,et al. Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma , 2017, Oncoimmunology.
[5] T. Whiteside,et al. Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients , 2017, Clinical Cancer Research.
[6] C. Scapulatempo Neto,et al. PD-1/PD-L1 and VEGF-A/VEGF-C expression in lymph node microenvironment and association with melanoma metastasis and survival , 2017, Melanoma research.
[7] J. Li,et al. The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta‐analysis , 2017, Scandinavian journal of immunology.
[8] J. Lang,et al. Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer , 2017, Oncotarget.
[9] G. Tse,et al. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients , 2017, Breast Cancer Research and Treatment.
[10] L. Gandhi,et al. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review. , 2016, JAMA oncology.
[11] J. Taube,et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.
[12] N. Matsumura,et al. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues , 2016, International Journal of Clinical Oncology.
[13] C. Porta,et al. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. , 2015, Cancer treatment reviews.
[14] Zhen-hua Hu,et al. Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. , 2011, Cytokine.
[15] J. Cheville,et al. Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma , 2011, Clinical Cancer Research.